Literature DB >> 36100641

Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Shenmiao Yang1, Neil E Kay2, Min Shi3, Curtis A Hanson3, Robert Peter Gale4.   

Abstract

Entities:  

Year:  2022        PMID： 36100641     DOI： 10.1038/s41375-022-01699-7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  52 in total

1.  Investigating the prognostic ability of health-related quality of life on survival: a prospective cohort study of adults with lung cancer.

Authors:  Laura C Pinheiro; Bryce B Reeve
Journal:  Support Care Cancer       Date:  2018-05-18       Impact factor: 3.603

Review 2.  Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

Authors:  Michelle K Wilson; Katherine Karakasis; Amit M Oza
Journal:  Lancet Oncol       Date:  2014-12-29       Impact factor: 41.316

3.  Quality of life as a prognostic factor for survival in hepatocellular carcinoma.

Authors:  Malin Sternby Eilard; Hannes Hagström; Kim Erlend Mortensen; Tom Wilsgaard; Ola Magne Vagnildhaug; Olav Dajani; Per Stål; Magnus Rizell
Journal:  Liver Int       Date:  2017-10-06       Impact factor: 5.828

4.  Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

Authors:  Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley
Journal:  J Natl Cancer Inst       Date:  2011-12-07       Impact factor: 13.506

5.  Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.

Authors:  Divine E Ediebah; Chantal Quinten; Corneel Coens; Jolie Ringash; Janet Dancey; Efstathios Zikos; Carolyn Gotay; Michael Brundage; Dongsheng Tu; Hans-Henning Flechtner; Eva Greimel; Bryce B Reeve; Martin Taphoorn; Jaap Reijneveld; Linda Dirven; Andrew Bottomley
Journal:  Cancer       Date:  2018-06-15       Impact factor: 6.860

6.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Authors:  Chantal Quinten; Corneel Coens; Murielle Mauer; Sylvie Comte; Mirjam A G Sprangers; Charles Cleeland; David Osoba; Kristin Bjordal; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

Review 7.  The prognostic significance of patient-reported outcomes in cancer clinical trials.

Authors:  Carolyn C Gotay; Crissy T Kawamoto; Andrew Bottomley; Fabio Efficace
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

Review 8.  Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology.

Authors:  Lisa M Hess; Alan Brnabic; Oksana Mason; Pablo Lee; Scott Barker
Journal:  J Cancer       Date:  2019-06-09       Impact factor: 4.207

9.  Evaluation of Reliability and Correlations of Quality Measures in Cancer Care.

Authors:  Nancy L Keating; Jessica L F Cleveland; Alexi A Wright; Gabriel A Brooks; Laurie Meneades; Lauren Riedel; Jose R Zubizarreta; Mary Beth Landrum
Journal:  JAMA Netw Open       Date:  2021-03-01

Review 10.  Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.

Authors:  Iman Abou Dalle; Elias Jabbour; Nicholas J Short
Journal:  Ther Adv Hematol       Date:  2020-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.